文献速递真菌感染

Rezafungin对比卡泊芬净治疗念珠菌血症与侵袭性念珠菌病的2期随机双盲STRIVE试验

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

STRIVE是一项2期双盲随机试验,比较每周一次Rezafungin与每日一次卡泊芬净治疗念珠菌血症和/或侵袭性念珠菌病的安全性与疗效。在微生物学意向治疗人群(183例)中,第14天总体治愈率:RZF 400mg组60.5%,RZF 400/200mg组76.1%,CAS组67.2%;30天全因死亡率分别为15.8%、4.4%和13.1%。结论认为Rezafungin安全有效。

要点

  • 第14天总体治愈率:RZF 400mg 60.5%,RZF 400/200mg 76.1%,CAS 67.2%。
  • 30天全因死亡率:RZF 400mg 15.8%,RZF 400/200mg 4.4%,CAS 13.1%。
  • 念珠菌血症清除时间:RZF组19.5小时,CAS组22.8小时。

核心结论

  • Rezafungin在治疗念珠菌血症和/或侵袭性念珠菌病中安全且有效。

研究设计与样本

  • 2期双盲随机试验,纳入207例有全身症状且真菌学确诊的念珠菌血症和/或侵袭性念珠菌病成人患者。
  • 患者随机分至RZF 400mg每周一次组、RZF 400mg第1周后200mg每周一次组、或CAS 70mg负荷后50mg每日一次组,疗程≤4周。

主要发现

  • 微生物学意向治疗人群183例(约21%为侵袭性念珠菌病),第14天总体治愈率:RZF 400mg组60.5%(46/76),RZF 400/200mg组76.1%(35/46),CAS组67.2%(41/61)。
  • 研究者评估的第14天临床治愈率:RZF 400mg组69.7%(53/76),RZF 400/200mg组80.4%(37/46),CAS组70.5%(43/61)。
  • 30天全因死亡率:RZF 400mg组15.8%,RZF 400/200mg组4.4%,CAS组13.1%。
  • 念珠菌血症清除时间:RZF组19.5小时,CAS组22.8小时。
  • 随访期间全因死亡率:RZF组15.2%(21/138),CAS组18.8%(13/69);未观察到令人担忧的安全性趋势。

临床怎么用

  • Rezafungin每周一次给药方案在念珠菌血症和/或侵袭性念珠菌病治疗中显示出与卡泊芬净相当的疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and/or invasive candidiasis (IC). METHODS: Adults with systemic signs and mycological confirmation of candidemia and/or IC were randomized to RZF 400 mg QWk (400 mg), RZF 400 mg on week 1 then 200 mg QWk (400/200 mg), or CAS 70 mg as a loading dose followed by 50 mg daily for ≤4 weeks. Efficacy assessments included overall cure (resolution of signs of candidemia/IC + mycological eradication) at day 14 (primary endpoint), investigator-assessed clinical response at day 14, and 30-day all-cause mortality (ACM) (secondary endpoints), and time to negative blood culture. Safety was evaluated by adverse events and ACM through follow-up. RESULTS: Of 207 patients enrolled, 183 were in the microbiological intent-to-treat population (~21% IC). Overall cure rates were 60.5% (46/76) for RZF 400 mg, 76.1% (35/46) for RZF 400/200 mg, and 67.2% (41/61) for CAS; investigator-assessed clinical cure rates were 69.7% (53/76), 80.4% (37/46), and 70.5% (43/61), respectively. In total, 30-day ACM was 15.8% for RZF 400 mg, 4.4% for RZF 400/200 mg, and 13.1% for CAS. Candidemia was cleared in 19.5 and 22.8 hours in RZF and CAS patients, respectively. No concerning safety trends were observed; ACM through follow-up was 15.2% (21/138) for RZF and 18.8% (13/69) for CAS. CONCLUSIONS: RZF was safe and efficacious in the treatment of candidemia and/or IC. CLINICAL TRIALS REGISTRATION: NCT02734862.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin Infect Dis. 2021. PMID: 32955088. doi:10.1093/cid/ciaa1380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。